JENKEM: Currently, the applicable U.S. tariff rate for the company's products has not changed

JENKEM stated on its interactive platform on October 15 that despite U.S. President Trump announcing high tariffs on various imported products starting October 1, the U.S. tariff rates applicable to the company's products have not changed. The stability of the company's cooperation with U.S. customers is not significantly affected, and it will continue to monitor changes in international trade policies to ensure stable business development

A-share innovative drug concept stocks fluctuated lower, with InventisBio falling over 10%. Other stocks such as Huahai Pharmaceutical, JENKEM, Lifeon Pharmaceutical, JOINN, Guangsheng Tang, HitGen, and Baillie Gifford also dropped more than 6%

JENKEM: Wu Kaiting plans to reduce his holdings by no more than 2%

According to the Zhitong Finance APP, JENKEM announced that due to the shareholder's own funding needs, Wu Kaiting plans to reduce his holdings of the company's shares by no more than 1.213 million shares through block trading within three months after the announcement is disclosed, with a proposed reduction ratio not exceeding 2% of the company's total share capital

Innovative drug concept stocks are repeatedly active, Chimin hits the daily limit

Innovative drug concept stocks are repeatedly active, Chimin hit the daily limit, JENKEM rose over 10%, YKYY, Nossan, Frontier Biotechnologies, Salubris, and HitGen followed suit

JENKEM: Actively exploring the optimization of existing R&D processes through AI

JENKEM stated on the interactive platform that it has formed a computational biology team to explore optimizing the R&D process through AI, particularly in key areas such as drug structure design and molecular screening. Although no significant results have been achieved yet, the short-term impact on performance is minimal, but the company is optimistic about the potential of AI in improving R&D efficiency and reducing costs